Cargando…
Apoptosis : pharmacological implications and therapeutic opportunities /
Programmed cell death (PCD) has become a topic of widespread interest and experimentation over the past decade. Written by experts in the field, Apoptosis: Pharmacological Implications and Therapeutic Opportunities concentrates on presenting an overview of PCD pathways as they are currently understo...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
San Diego :
Academic Press,
�1997.
|
| Colección: | Advances in pharmacology (San Diego, Calif.) ;
41. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo Texto completo |
Tabla de Contenidos:
- Front Cover; Apoptosis: Pharmacological Implications and Therapeutic Opportunities; Copyright Page; Contents; Contributors; Foreword; Part 1: Biology of Cell Death; Chapter 1. Apoptosis: An Overview of the Process and Its Relevance in Disease; I. Introduction; ll. Morphology of Apoptosis; lll. Genetics and Biochemistry of Apoptosis; IV. Apoptosis as a Therapeutic Target; V. Conclusion; References; Chapter 2. Genetics of Apoptosis; I. Introduction; II. Programmed Cell Death Pathway in C. elegans; III. Apoptosis in Drosophila melanogaster; VI. Apoptosis in Mammals.
- v. Viral Genes Involved in Host Cell ApoptosisVI. Programmed Cell Death in Unicellular Organisms; VII. Conclusion; References; Chapter 3. Methods Utilized in the Study of Apoptosis; I. Introduction; ll. Detection of PCD Based on Morphology; lll. Detection of DNA Fragmentation; IV. Terminal Deoxyribonucleotidyl Transferase-Mediated dUTP Nick end Labeling (TUNEL); V. Flow Cytometry; VI. Annexin V Staining; VII. Alterations in Plasma Membrane Permeability; VIII. Enzyme Assays; IX. Use of Inhibitors to Study Apoptotic Processes; Chapter 4. In Vitro Systems for the Study of Apoptosis.
- I. Introduction of Cell-Free Systems for Apoptosis Studiesll. Examples of Cell-Free Systems; lll. Criteria for Relevant Systems; IV. Biochemical Dissection of in Vitro Systems; V. Future Directions; References; Chapter 5. The Fas Pathway in Apoptosis; I. Introduction; ll. Fas; lll. Fas Ligand; IV. Regulatory Roles of Fas and FasL; V. Signaling from the Fas Receptor; VI. Fas/FasL-Associated Disease States; VII. Modulating Fas and/or FasL for Therapeutic Purposes; VIII. Conclusion; References; Chapter 6. Ceramide: A Novel Lipid Mediator of Apoptosis; I. Introduction; ll. The Sphingomyelin Cycle.
- Lll. ApoptosisIV. Conclusions and Prospects for the Future; References; Chapter 7. Control of Apoptosis by Proteases; I. Introduction; ll. The ICE/CED-3 Family of Proteases; lll. Other Proteases Implicated in Apoptosis; IV. Proteases as Therapeutic Targets in Apoptosis; References; Part 2: Apoptosis under Physiologic Conditions; Chapter 8. Death and Dying in the Immune System; I. Death; ll. Dying; lll. Summary; References; Chapter 9. Control of Apoptosis by Cytokines; I. Introduction; ll. Cytokines and Survival; lll. Hematopoietic Growth Factors/Cytokines and Antiapoptotic Signals.
- IV. Unresolved Issues Concerning Apoptotic SignalsV. Novel Therapeutic Strategies Targeting Apoptosis: Tipping the Balance; References; Chapter 10. Glucocorticoid-Induced Apoptosis; I. Introduction; ll. The Decision to Die: Role of the Glucocorticoid Receptor and Glucocorticoid-Regulated Gens; Ill. The Decision to Die: Cell Cycle Arrest and Mtabolic Changs; IV. The Decision to Die: Regulation by Cytokines and T Cell Receptor; V. Execution Phase: Role of Proteases; VI. Execution and Degradation: Role of Calcium; VII. Execution and Degradation: Role of Oxygen Radicals.